Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: FURESTEM-RA Inj.
- Registration Number
- NCT03106259
- Lead Sponsor
- Kang Stem Biotech Co., Ltd.
- Brief Summary
Observational Study to evaluate the safety of FURESTEM-RA lnj. in moderate to severe rheumatoid arthritis patients who participated in phase 1 clinical trial of FURESTEM-RA lnj.
- Detailed Description
This is a observational study, single center, open label, study of safety of FURESTEM-RA Inj. in subjects with moderate to severe rheumatoid arthritis.
Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.
\[NCT02221258\]
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
- Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.[NCT02221258]
- Subject who understands and voluntarily sign an informed consent form
Exclusion Criteria
- In case follow-up is not possible from end of clinical trial Phase 1 to end of this study period
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Non-Interventional Study FURESTEM-RA Inj. Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.\[NCT02221258\]
- Primary Outcome Measures
Name Time Method Safety of FURESTEM-RA Inj. 5 years Evaluate the number of adverse events Safety of FURESTEM-RA Inj.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Seoul national University Boramae medical center
🇰🇷Seoul, Korea, Republic of
Seoul national University Boramae medical center🇰🇷Seoul, Korea, Republic of